Veru (NASDAQ:VERU) Price Target Increased to $3.00 by Analysts at HC Wainwright

Veru (NASDAQ:VERU) had its target price boosted by HC Wainwright from $2.00 to $3.00 in a report released on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Other equities analysts have also issued research reports about the company. Raymond James initiated coverage on Veru in a research note on Thursday, March 28th. They set an outperform rating and a $3.00 price objective on the stock. Oppenheimer restated an outperform rating and issued a $5.00 price target (down previously from $7.00) on shares of Veru in a research report on Monday, April 15th.

Veru Price Performance

Shares of Veru stock opened at $1.64 on Monday. The firm has a 50-day moving average of $0.96 and a 200-day moving average of $0.80. Veru has a 52-week low of $0.36 and a 52-week high of $1.92.

Veru (NASDAQ:VERU) last posted its quarterly earnings data on Monday, April 1st. The company reported ($0.09) earnings per share (EPS) for the quarter. Veru had a negative net margin of 405.04% and a negative return on equity of 257.92%. The business had revenue of $2.14 million during the quarter. As a group, equities analysts forecast that Veru will post -0.26 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in VERU. Perceptive Advisors LLC boosted its holdings in shares of Veru by 412.4% in the 4th quarter. Perceptive Advisors LLC now owns 5,584,699 shares of the company’s stock valued at $4,021,000 after purchasing an additional 4,494,821 shares in the last quarter. Octagon Capital Advisors LP bought a new stake in shares of Veru during the 4th quarter worth $2,736,000. AIGH Capital Management LLC acquired a new stake in Veru in the fourth quarter valued at about $2,476,000. Worth Venture Partners LLC bought a new position in Veru in the fourth quarter valued at about $616,000. Finally, ADAR1 Capital Management LLC acquired a new position in Veru during the fourth quarter worth about $360,000. 47.16% of the stock is owned by institutional investors.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.